Loading...
| Jan 01, 1970 | Daily Report |
| RISING BHARAT | News Count (102624) | |
20511. COVID-19 vaccination voluntary, no provision of insurance for side-effects: Govt
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Mint
|
- India started nationwide COVID-19 vaccine drive started on 16 January with healthcare and essential workers
- For Covishield vaccine, a total of 8,402 AEFIs, i.e. 0.192% AEFI cases have been reported out of total beneficiaries vaccinated, Choubey said
- There is no provision of insurance for recipients of coronavirus vaccine against any kind of side affects or medical complications that may arise due to inoculation, Ashwini Choubey, minister of health informed Rajya Sabha on Tuesday.
20512. Covishield Vaccine: ब्रिटेन भेजे जाने वाली 50 लाख 'कोविशील्ड' वैक्सीन को भारत में ही यूज किया जाएगा
India Fights Corona: Vaccination Drive and Initiatives
Hindi
India
ABP Live
|
- ब्रिटेन भेजे जाने वाली 'कोविशिल्ड' वैक्सीन की 50 लाख डोज का इस्तेमाल अब भारत में ही किया जाएगा. ये डोज देश के 21 राज्यों या केंद्र शासित प्रदेशों में 18-44 उम्र के लोगों के लिए उपलब्ध कराने का निर्णय किया गया है.
- इन डोज को पहले सीरम इंस्टीट्यूट द्वारा ब्रिटेन भेजा जाना था. मंत्रालय ने राज्यों से कंपनी से संपर्क करने और खरीद गतिविधि को तुरंत शुरू करने के लिए कहा है. कुछ राज्यों को 3,50,000 खुराकें आवंटित की गई हैं.
- अन्य को 1-1 लाख खुराकें मिली हैं और दो अन्य को 50-50 हजार खुराकें मिली हैं. इन टीकों पर कोविशील्ड नहीं बल्कि ‘कोविड-19 वैक्सीन एस्ट्राजेनेका’ का लेबल लगाया गया है.
20513. India orders 14.5 million more Covid-19 vaccine doses as campaign expands
India Fights Corona: Vaccination Drive and Initiatives
English
India
Hindustan Times
|
- SII, the world's biggest vaccine maker, had supplied 11 million doses for the inoculation campaign, which has covered 6.3 million front-line workers since it began on Jan. 16.
- "The second order is already in place, it's for 10 million doses," an SII spokesman said, adding that the figure was part of the 100 million doses the company has agreed to sell to the government for 200 rupees ($2.74) each.
- Bharat Biotech, which developed its vaccine with the state-run Indian Council of Medical Research, has supplied 5.5 million doses. A Bharat Biotech spokeswoman said it was selling 4.5 million more.
20514. NIT Andhra Pradesh researchers create technology to monitor and control electrical loads
Innovation and startups, ISRO/Defense/Water infrastructure/EV and other sectors
->
Innovations in Bharat
English
India
India Today
|
- Researchers at National Institute of Technology (NIT) Andhra Pradesh have developed a 'Edge Computing Stack' that uses Smart Powerline communications for monitoring and controlling electrical loads
- Designed to check the consumption of electrical appliances, this device is based on Internet-of-Things (IoT).
- The patent's distinctive addition is the optimal use of both Wi-Fi and Power Line Communications, whereas prior systems mostly relied on Wi-Fi, Bluetooth, or a mix of the two.
20515. Covid-19 vaccination drive: Over 68 lakh people inoculated in India so far
India Fights Corona: Vaccination Drive and Initiatives
English
India
Mint
|
- India will start distributing the second dose of coronavirus vaccine to beneficiaries from 13 February
- The nationwide Covid-19 vaccine drive started on 16 January.
- Out of the total, the number of healthcare workers who have been inoculated stands at 56,65,172 and the number of frontline workers are 1161728
20516. Biocon Biologics buys Viatris’ biosimilars business in $3.3 bln deal; Mazumdar-Shaw to continue as chairperson
Bharat Economic Growth
->
Bharat Economic Growth
English
India
Financial Express
|
- Biocon Biologics Ltd (BBL), a unit of BSE-listed Biocon Ltd, said it has agreed to acquire biosimilar business from US-based healthcare firm Viatris Inc for $3.335 billion in stock and cash.
- Nasdaq-listed Viatris will receive up to $2.335 billion and compulsorily convertible preference shares worth $1 billion or equivalent equity stake of 12.9% in Biocon Biologics, the company said
- A biosimilar, akin to its name, is a copy of an existing biologic drug. It is a drug made from proteins or pieces of proteins.
Click here to find 1469 similar incidents of Bharat Economic Growth -> Bharat Economic Growth
20517. WHO expert panel recommends wide use of AstraZeneca Covid vaccine
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
The Times Of India
|
- The benefits of the Covid-19 vaccine developed by AstraZeneca and Oxford University outweigh any risks and the shot should recommended for use, including in people aged 65 and older, a World Health Organization panel said on Wednesday.
- In interim recommendations on the shot, the Strategic Advisory Group of Experts on Immunisation (SAGE) panel said the vaccine should be given in two doses, with an interval of around 8 to 12 weeks between the first and second doses.
- SAGE also said that even where questions have been raised about the vaccine's efficacy against a South African variant of the coronavirus, "there is no reason not to recommend its use".South Africa this week paused its rollout of the AstraZeneca vaccine after data from a small trial showed it did not protect against mild to moderate illness from the 501Y.V2 variant of the coronavirus now dominant in the country.
20518. UK extends COVID-19 vaccine supply deal with India's Wockhardt by 6 months
Make in India / Atmanirbhar
->
Make in India- Public Health and Infrastructure
English
India
Mint
|
- The agreement is now expanded to August 2022 and will continue to make vaccines at CP Pharmaceuticals, a subsidiary of the company in Wrexham, North Wales
- The Wockhardt Ltd. plant, a site used in the production of the AstraZeneca Plc and the University of Oxford Covid-19 vaccine, in Wrexham, U.K
- The United Kingdom has extended Covid-19 vaccine deal with India's pharma company Wockhart by up to 6 months, the company said in a regulatory filing on Wednesday.
20519. Canadian regulator authorises AstraZeneca COVID-19 vaccine
Indian Diplomacy
->
Economic and Medical Support to Other Countries
English
India
The New Indian Express
|
- Third COVID-19 vaccine given the green light by Canada, following those from Pfizer and Moderna
- Canada has now ordered 22 million doses of the AstraZeneca shot, which was co-developed by researchers at the University of Oxford. It will also receive up to 1.9 million doses through the global vaccine-sharing initiative known as COVAX by the end of June.
- Trudeau said 2 million of those doses will come from the Serum Institute of India, which Sharma said uses the same recipe but a slightly different method and was also approved. The AstraZeneca vaccine has already been authorized in more than 50 countries.
20520. COVID-19 vaccine to cost Rs 250 per dose in private hospitals, only Covishield to be available
India Fights Corona: Vaccination Drive and Initiatives
English
India
The New Indian Express
|
- As per the agreement between the manufacturers, representatives of private hospitals and the government, the vaccine makers will get Rs 150 per jab while hospitals will earn Rs 100 per shot for every dose of the vaccine administered.
- “States have been explained that the private hospitals functioning as Covid vaccination centres can be subject to a ceiling of Rs 250 per person per dose along with the electronic and financial management mechanism in this regard,” the ministry said in a statement.
- Around 10,000 private hospitals empanelled under the Pradhan Mantri Jan Arogya Yojana, nearly 687 hospitals empanelled under the Central Government Health Scheme and other private hospitals empanelled under state health insurance schemes can participate in the vaccination drive